Thomas Michael Lewis is a pharmacist who is specialized in Nuclear in Albany, New York. Patients can reach him at 25 Walker Way Ste 3d, Albany or contact him on 518-464-0871. Active license number of Thomas Michael Lewis is 038052 for Nuclear in New York. Thomas Michael Lewis is a licensed pharmacist who has demonstrated specialized knowledge and skill in procurement, compounding, quality control testing, dispensing, distribution, and monitoring of radiopharmaceuticals.
Complete Profile:
Thomas Michael Lewis speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Thomas Michael Lewis
Specialization:
Nuclear
Credentials:
RPH.
Gender:
Male
Location:
25 Walker Way Ste 3d, Albany, New York, 12205-4963
Phone:
518-464-0871
Fax:
518-464-0874
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Thomas Michael Lewis are as mentioned below.
NPI Number:
1548740046
NPI Enumeration Date:
15 Aug, 2018
NPI Last Update On:
15 Aug, 2018
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Thomas Michael Lewis are as mentioned below.
Specialization
License Number
State
Status
Nuclear
038052
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
25 Walker Way Ste 3d, Albany, New York
Zip:
12205-4963
Phone Number:
518-464-0871
Fax Number:
518-464-0874
Patients can reach Thomas Michael Lewis at 25 Walker Way Ste 3d, Albany, New York or can call on phone at 518-464-0871.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 October, 2025.